NCT07295717

A Study to Evaluate ALN-4285 in Adult Healthy Volunteers

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-4285 in Adult Healthy Volunteers

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 76 (estimated)
• Sponsor: Alnylam Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to: * evaluate the safety and tolerability of single ascending doses of ALN-4285 in healthy volunteers * characterize the single-dose pharmacokinetics (PK) of ALN-4285

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	ALN-4285	ALN-4285 will be administered SC
DRUG	Placebo	Placebo will be administered SC

Timeline

• Start date: 2025-12-12
• Primary completion: 2026-12-29
• Completion: 2027-03-23
• First posted: 2025-12-22
• Last updated: 2026-04-17

Locations

1 site across 1 country: United Kingdom